


Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1 - 7 (canceled).

8. (currently amended) A dosage form comprising a compound of formula 1:



1

or a pharmaceutically acceptable salt thereof, in an amount of ~~no more than~~ from 0.5 to 30 mg.

9. (canceled).

10. (original) The dosage form of claim 8, wherein the amount is from 1 to 20 mg.

11. (original) The dosage form of claim 8, wherein the amount is from 1.5 to 15 mg.

12. (original) The dosage form of claim 8, wherein the amount is from 2 to 10 mg.

13. (original) The dosage form of claim 8, wherein the amount is from 2.5 to 8 mg.


14. (original) The dosage form of claim 8, wherein the amount is from 3 to 7 mg.

15. (original) The dosage form of claim 8, wherein the dosage form is an oral dosage form.

16. (original) The dosage form of claim 8, wherein the dosage form is a tablet or capsule.

17- 31 (canceled).

32. (currently amended) A method of treating VEGF-, PDGF- or c-Kit-related cancer in a mammal, the method comprising administering to the mammal a compound of formula 1:



1

or a pharmaceutically acceptable salt thereof, in an amount of ~~no more than~~ from 0.5 to 30 mg per dose.

33. (canceled).

34. (original) The method of claim 32, wherein the amount is from 1 to 20 mg.

35. (original) The method of claim 32, wherein the amount is from 1.5 to 15 mg.

36. (original) The method of claim 32, wherein the amount is from 2 to 10 mg.

37. (original) The method of claim 32, wherein the amount is from 2.5 to 8 mg.

38. (original) The method of claim 32, wherein the amount is from 3 to 7 mg.

39. (original) The method of claim 32, wherein the compound is administered orally.

40. (original) The method of claim 32, wherein the compound is administered at a dosage frequency of at least once per day.

41. (original) The method of claim 32, wherein the compound is administered at a dosage frequency of at least twice per day.

42-45 (canceled).

46. (previously presented) The method of claim 32, wherein the cancer is selected from lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's

Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, and combinations thereof.

47-48 (canceled).

49. (previously presented) The method of claim 46, wherein the cancer is cancer of the thyroid gland or cancer of the parathyroid gland, and wherein the compound is administered in an amount of from 1 mg to 20 mg per dose at a dosage frequency of twice per day.

50. (previously presented) The method of claim 46, wherein the cancer is breast cancer, and wherein the compound is administered in an amount of from 1 mg to 20 mg per dose at a dosage frequency of twice per day and wherein the method further comprises co-administering docetaxel.

51. (previously presented) The method of claim 46, wherein the cancer is pancreatic cancer, and wherein the compound is administered in an amount of from 1 mg to 20 mg per dose at a dosage frequency of twice per day and wherein the method further comprises co-administering gemcitabine.